Article
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
All News
Article
A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs).
Article
Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.
Article
What is the optimal glucocorticoids (GC) regimen in giant cell arteritis (GCA)? Does methotrexate (MTX) work in GCA?
Article
While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD.
Dr. John Cush
Tweet
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/IyCsJOm9PS https://t.co/PgDKanxaNU
Dr. John Cush
Tweet
Screening for RA-ILD: metanalysis of 9 studies, 1380 RA pts - RA-ILD prevalence ranged from 6.7-42.7%; 18.9% via HRCT. None examined risk factors. Male sex & smoking were ~12% higher in RA-ILD & RA disease onset age was 7 years higher in RA-ILD pts. DAS didnt https://t.co/qA2oitwQg5
Dr. John Cush
Tweet
Inception SLE study of 674 pts (without LN), mean age 34 yrs - 154 (23%) developed new proteinuria (LN) after median of 3.6 yr. Cumulative antimalarial exposure did NOT lower risk of LN (HR 0.98; 0.94-1.02); same for those w/ serologically active SLE (HR 0.97) https://t.co/8OU3yJAvhN
Dr. John Cush
Tweet
Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in ED or hospitalization. But NSIA led to missed work (37%) or RA Rx interruptions (26%) and more fatigue. NSIE may contribute to more disease flares https://t.co/Al5B5oxvFg
Dr. John Cush
Tweet
DERM on RheumNow Podcast (September 2025)
Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.
https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E
Dr. John Cush
Tweet
Scleroderma-associated Interstitial Lung Disease
Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF
Dr. John Cush
Tweet
Big Fat FDA Pink Slip (9.19.2025)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip.
https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt
Dr. John Cush
Tweet
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk
Dr. John Cush
Tweet
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v
Dr. John Cush
Tweet
Did Hydroxychloroquine Reduce COVID-19 Mortality?
A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on https://t.co/BuHoMDwpuP
Dr. John Cush
Tweet
Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N
Dr. John Cush
Tweet
Equal Safety of JAK Inhibitors and TNF Inhibitors
JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
Dr. John Cush
Tweet
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia
Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months.
https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt
Dr. John Cush
Tweet
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/XNmbcfqKKF
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh
Luis Caminal
Tweet
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score study https://t.co/kmLy6NXFO1
